RU-486 Review Focus On "Intended Use" Is Appropriate - Henney
Executive Summary
FDA approval of the abortifacient mifepristone (RU-486) is appropriate provided that the drug is safe and effective for its intended use by pregnant women for termination of pregnancy, FDA Commissioner nominee Jane Henney, MD, told the Senate Labor & Human Resources Committee Aug. 24.
You may also be interested in...
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011